Drugs / YS5 antibody
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05245006 | Mar 2022 → Jul 2027 expected | castration-resistant prostate carcinoma | University of California, San Francisco | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YS5 antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05245006 ↗ |
| Route | Intravenous | “20 or 50 mg administered intravenously” NCT05245006 ↗ |